Monthly Archives: December 2011

The recently approved treat Incivek, combined with two guidon drugs, is extraordinarily efficacious at treating hepatitis C, a notoriously difficult-to-manage liver disease, two imaginative studies show. The deaden innards not only in patients just starting treatment, but in those who … Continue reading →

Is the hepatitis-C market the next Mecca for the pharma/biotech sector? It seems so if we go by the flurry of activity and heightened interest in this market in the past few quarters. The hepatitis-C virus (HCV) market seems to … Continue reading →

Welcome to MM&M’s Pipeline 2012, a guide to late-stage R&D and a tip sheet on what’s generating the most buzz in drug development. Scrutinizing the new crop of front-runners, readers may ask themselves: Is the blockbuster still alive? As pharma … Continue reading →

Pfizer ($PFE) has been gearing up for the expiration of Lipitor’s patent for years, and with the big day finally upon us, analysts and industry watchers are weighing in on the R&D course that the drug giant has plotted to … Continue reading →

To lead in global pharmaceutical and biotechnology strategy and investments by maintaining an in-depth understanding and worldwide perspective on the industry, and to work closely with investors and senior managers to enhance their strategic choices. TOC – Therapeutic and Special … Continue reading →